KR100371549B1 - Development of fermented dairy products containing CLA - Google Patents

Development of fermented dairy products containing CLA Download PDF

Info

Publication number
KR100371549B1
KR100371549B1 KR10-2000-0014858A KR20000014858A KR100371549B1 KR 100371549 B1 KR100371549 B1 KR 100371549B1 KR 20000014858 A KR20000014858 A KR 20000014858A KR 100371549 B1 KR100371549 B1 KR 100371549B1
Authority
KR
South Korea
Prior art keywords
cla
fermented milk
lactic acid
acid bacteria
weight
Prior art date
Application number
KR10-2000-0014858A
Other languages
Korean (ko)
Other versions
KR20010089858A (en
Inventor
김세헌
오세종
김영준
킴 데이비드
Original Assignee
김세헌
오세종
김영준
킴 데이비드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김세헌, 오세종, 김영준, 킴 데이비드 filed Critical 김세헌
Priority to KR10-2000-0014858A priority Critical patent/KR100371549B1/en
Publication of KR20010089858A publication Critical patent/KR20010089858A/en
Application granted granted Critical
Publication of KR100371549B1 publication Critical patent/KR100371549B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/51Bifidobacterium
    • A23V2400/533Longum

Abstract

본 발명은 씨엘에이(CLA : Conjugated Linoleic Acid, 공액리놀레인산)를 함유하는 발효유 조성물에 관한 것으로서, 본 발명의 목적은 발효유의 정장효과와 CLA의 항암효과가 상호 유기적으로 작용하여 보다 향상된 기능성과 정장제, 사료첨가제 및 분말 유산균 제품의 제조에 적절히 이용될 수 있는 CLA를 함유하는 발효유 조성물을 제공함에 있다.The present invention relates to a fermented milk composition containing CLA (Conjugated Linoleic Acid, conjugated linoleic acid), an object of the present invention is to improve the functionality and functionalities of the anticancer effect of the fermented milk and the anti-cancer effect of CLA It is to provide a fermented milk composition containing CLA that can be suitably used in the preparation of a formal, feed additives and powdered lactic acid bacteria products.

본 발명의 상기 목적은 유산균을 이용하여 발효유 내의 유효성분으로서 CLA를 0.5~2 중량%를 함유하는 발효유 조성물로서 유산균을 이용하여 발효유 내의 유효성분으로서 CLA를 0.5~2중량%를 함유하여 높은 항동맥 경화와 항암효과로서 인체 건강에 유용하게 활용될 수 있는 효과와 정장제, 사료첨가제 및 분말 유산균 제품의 제조에 적절히 이용할 수 있음으로서 산업발전에 유용한 효과가 있다.The above object of the present invention is a fermented milk composition containing 0.5 to 2% by weight of CLA as an active ingredient in fermented milk using lactic acid bacteria. As a hardening and anticancer effect, it can be usefully used for human health and can be suitably used in the preparation of formal preparations, feed additives and powdered lactic acid bacteria products, which has a useful effect in industrial development.

Description

CLA를 함유하는 발효유 조성물{Development of fermented dairy products containing CLA}Development of fermented dairy products containing CLA

본 발명은 씨엘에이(CLA : Conjugated Linoleic Acid, 공액리놀레인산)를 함유하는 발효유 조성물에 관한 것으로서, 보다 상세하게는 발효유의 정장효과와 CLA의 항암효과가 상호 유기적으로 작용하여 보다 향상된 기능성과 정장제, 사료첨가제 및 분말 유산균 제품의 제조에 적절히 이용될 수 있는 CLA를 함유하는 발효유 조성물에 관한 것이다.The present invention relates to a fermented milk composition containing CLA (Conjugated Linoleic Acid, conjugated linoleic acid), and more specifically, the anticancer effect of fermented milk and the anticancer effect of CLA interact with each other organically for improved functionality and formant. It relates to a fermented milk composition containing CLA which can be suitably used for the preparation of feed additives and powdered lactic acid bacteria products.

최근에 이르러 현대인의 소득수준이 향상됨에 따라서 고 단백질, 고 콜레스테롤의 음식을 많이 접하게 되었고, 이로 인하여 각종 성인성 질환이 급증하였으며, 그 중 암과 동맥경화 등이 현대인의 사망요인으로 매우 중요하게 인식되어 왔다. 이들 질환과 관련하여 유산균 및 발효유 제품에 대한 여러 가지 연구가 개시되었으며, 그 결과 인체에 유용한 다양한 유산균이 개발되었고, 이러한 유산균을 함유한 발효유 제품이 다양하게 상품화되고 있다.In recent years, as the income level of modern people has improved, a lot of foods of high protein and high cholesterol have been encountered, and as a result, various adult diseases have increased rapidly. Among them, cancer and arteriosclerosis are considered as important death factors of modern people. Has been. In connection with these diseases, various studies on lactic acid bacteria and fermented milk products have been disclosed. As a result, various lactic acid bacteria useful for the human body have been developed, and various fermented milk products containing such lactic acid bacteria have been commercialized.

유산균 발효유 제품은 우유와 함께 우리 나라는 물론 외국의 대다수 나라에서 일상 섭취하는 주요한 식품으로 일상의 생활에 자리를 잡아가고 있다.Lactobacillus fermented milk products, along with milk, are the main foods consumed in our country as well as in most foreign countries.

초기 유산균 발효유 제품의 유래는 정확하지는 않으나, 생산자가 향미(香味)성 요인을 모르는 상태에서 저장성을 높이기 위해 발효식품을 제조한 것으로 보여지고 있고, 최근에 이르러서는 발효과정의 조정 및 인체에 유용한 물질 함유를 통하여 제품의 질이 향상된 발효유 제품이 다양하게 선보이고 있다.Although the origin of early lactic acid bacteria fermented milk products is not accurate, it has been shown that producers manufactured fermented foods to increase shelf life without knowing flavor factors, and recently, substances useful for the adjustment of fermentation process and human body Fermented milk products have been introduced in a variety of ways to improve the quality of their products.

이러한 발효유 제품이 영양생리학적으로 우수한 식품으로 자리를 잡아가고 있는 것은 정기적인 체내 흡수 시에는 장수 및 건강에 좋다고 알려져 있기 때문으로 사료된다.This fermented milk product is becoming a nutritionally physiologically superior food because it is known to be good for longevity and health when absorbed regularly in the body.

유산균 제품에 의한 건강증진 효과는 유산균의 배양을 통하여 형성된 대사산물이 장내 부패균의 성장을 억제함에 기인하는 것으로 알려져 있고, 이러한 인체에 유용한 유산균을 함유하는 발효유는 제품의 보관성면에서 볼 때, 우유에 비하여 품질보존이 용이한 점, 소화흡수성이 높은 점, 지방의 부분적인 분리에 의한 지방산 유리효과가 높은 점, 장내의 병원성 균의 감염을 저지할 수 있다는 점, 장내의 유해균의 증식을 억제하여 항암효과를 직, 간접적으로 얻을 수 있다는 점, 혈중의 콜레스테롤의 저하작용이 있다는 점 외에도 변비와 설사 억제, 유해균에 대한 면역체계를 증진시킨다는 점등의 여러 가지 인체에 건강증진 효과를 가지고 있기 때문에 다양하게 상품화되고 있는 것이 현 실정이다.The health-promoting effect of lactic acid bacteria products is known to be due to the inhibition of the growth of intestinal rot by the metabolites formed through the culture of lactic acid bacteria. Fermented milk containing lactic acid bacteria useful for the human body is found in milk, in terms of storage properties of the product. Compared with its easy-to-preserve quality, high digestive absorption, high fatty acid free effect by partial separation of fat, it can prevent infection of pathogenic bacteria in the intestine, and anti-cancer by inhibiting the growth of harmful bacteria in the intestine. In addition to its direct and indirect effects, and its lowering of cholesterol in the blood, it has a variety of products that promote health in the human body, which helps to suppress constipation and diarrhea and enhances the immune system against harmful bacteria. It is the present situation that is becoming.

이러한 산업적 이용가치가 있는 유산균은 최근까지 끊임없는 개량을 통하여 선발되고 있는데, 이러한 유용 균주들이 인체나 동물에게 유익하게 작용하려면 장내에 정상적으로 존재하는 균주이어야 하고, 소화기관을 통과하면서 생존해야 하며, 장내에서 정착이 가능한 균주이어야만 상기에서 언급한 여러 가지 건강증진효과가 보장이 될 것이다.Lactobacillus with industrial value has been selected through continuous improvement until recently. In order for these useful strains to benefit humans or animals, they must be normally present in the intestine, survive through the digestive system, and enter the intestine. Only if the strain can be settled in the various health promotion effects mentioned above will be guaranteed.

한편, 씨엘에이(CLA)란 cis 혹은 trans 배열에 공액화 2중결합 (conjugated double bonds)을 가지고 있는 리놀레인산의 위치적 및 형태적 이성체(positional and geometric isomers)를 일컫는 일반적인 명칭이다. 이들 CLA는 9, 11위치 및 10, 12위치에 cis 혹은 trans 배열을 하기도 하며, 이론적으로는 리놀레인산(cis-9, cis-12 octadecadienoic acid)의 이성화반응에 의하여 8개의 9, 11 옥타데카디에노인산(octadecadienoic acid) 및 10, 12 옥타디카디에노인산(cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12; cis-10, trans-12; trans-10, cis-12 및 trans-10, trans-12)이 형성될 수가 있다.On the other hand, CLA is a generic name for the positional and geometric isomers of linoleic acid having conjugated double bonds in the cis or trans configuration. These CLAs also have cis or trans arrays at positions 9, 11 and 10, 12. In theory, 8 C9s, 11 octadecas are formed by isomerization of linoleic acid (cis-9, cis-12 octadecadienoic acid). Octadecadienoic acid and 10, 12 octadecadienoic acid (cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis -10, cis-12; cis-10, trans-12; trans-10, cis-12 and trans-10, trans-12) can be formed.

그러나, 자연적으로 여러 가지 식품에 존재하는 CLA, 특별히 반추동물 유래의 유제품 및 육류에 천연적으로 함유되어 있으며, 발견되는 총 CLA중 cis-9, trans-11 옥타데카디에노인산이 85∼95%를 차지하고 있다(TransFatty Acids in Human Nutrition : edited by J. L Sebedio and W.W Christie. 1998.Chapter 9. 261∼302page. The Oilypress Ltd).However, CLA, especially ruminant-derived dairy products and meats, which are naturally present in many foods, contains 85-95% of cis-9 and trans-11 octadecadienoic acid. (TransFatty Acids in Human Nutrition: edited by J. L Sebedio and WW Christie. 1998. Chapter 9. 261 to 302. The Oilypress Ltd).

이러한 씨엘에이(CLA)는 높은 항동맥경화를 지님과 동시에(Lee, K. N. 등 1994, Atherosclerosis 108:19) 특히, 동물실험에서 발암물질에의 노출로 인한 대장암, 위암, 유방암 및 피부암 유발을 억제하는 작용을 가진 것으로 보고 되었다(Ha, Y. L. 등 1990, Cancer Res. 50:1097; Belury, M. A. 등 1996, Nutr. Cancer 26:149; Ip, C. 등 1991, Cancer Res. 50:6118; Liew, C. 등 1996, Carcinogenesis 16:3037).While these CLAs have high anti-arteriosclerosis (Lee, KN et al. 1994, Atherosclerosis 108: 19), they inhibit the induction of colorectal, gastric, breast and skin cancers due to exposure to carcinogens in animal experiments. (Ha, YL et al. 1990, Cancer Res. 50: 1097; Belury, MA et al. 1996, Nutr. Cancer 26: 149; Ip, C. et al. 1991, Cancer Res. 50: 6118; Liew, C. et al. 1996, Carcinogenesis 16: 3037).

CLA 함량을 식품에서 분석하는 방법으로는 가스크로마토그래피 (Gas Chromatography)를 주로 이용하는데, 추출하는 조건 및 분석하는 방법에 따라서 다소 차이가 있다.As a method of analyzing CLA content in food, gas chromatography (Gas Chromatography) is mainly used, but there are differences depending on the extraction conditions and the method of analysis.

본 발명자는 씨엘에이(CLA) 생성에 관여하는 요인을 분석하여 그 함량을 증가시키는 연구를 수행한 결과 새로운 씨엘에이(CLA) 분석방법을 정립할 수 있었다(동일 출원인에 의한 미합중국 Journal of Food Science 학회지 64권 5호 792쪽).As a result of analyzing the factors involved in the production of CLA and increasing its content, the inventors were able to establish a new method for analyzing CLA (the Journal of the US Journal of Food Science by the same applicant) 64, no. 5, p. 792).

이러한 방법을 이용하면 보다 효과적으로 씨엘에이(CLA) 함량을 측정 할 수 있을 것이다.Using this method will be able to measure the CLA content more effectively.

또한, 낙농제품 중에는 천연적으로 씨엘에이(CLA)를 미량함유하고 있으나 (Chin, S. F. 등 1992, J. Food Comp. Anal. 5:185) 항암효과를 보이는 수준에는 미치지 못하기 때문에 씨엘에이(CLA) 함량을 제품 내에서 증가시키는 것이 요구된다. 동물 실험 결과 씨엘에이(CLA) 섭취량이 식품 중 0.1% 이상인 경우에 효과적으로 발암을 억제하는 것으로 나타났으며, 이는 낙농식품을 주식으로 하는 미국인 평균 씨엘에이(CLA) 섭취량의 3배에 해당하는 수치이다(Ip, C. 등 1994, Cancer Res. 54:1212).In addition, dairy products naturally contain trace amounts of CLA (Chin, SF et al. 1992, J. Food Comp. Anal. 5: 185). ) Increasing the content in the product. Animal studies have shown that CLA intake is more than 0.1% of food, effectively inhibiting carcinogenesis, which is three times the average CLA intake of dairy foods as a staple. (Ip, C. et al. 1994, Cancer Res. 54: 1212).

이러한 씨엘에이(CLA)를 낙농식품 중에 다량 함유하게 하는 방법으로는 정제된 씨엘에이(CLA), 또는 씨엘에이(CLA)를 많이 함유하고 있는 지방질의 인위적 첨가 등이 있으나 제조 과정 중에 첨가하게 되면 제조공정상 소실될 우려가 있으며 가격이 높아지게 되는 단점이 있다.The method of containing a large amount of CLA in dairy foods includes artificial addition of purified CLA or CLA, but if it is added during the manufacturing process, There is a risk of normal loss and the price increases.

따라서, 본 발명은 상기의 문제점을 해결하기 위한 것으로서,Therefore, the present invention is to solve the above problems,

본 발명의 목적은 씨엘에이(CLA)를 생성하는 유산균을 선발하여 그 유산균을 발효유 제조에 이용함으로서, 발효유의 정장효과와 CLA의 항암효과가 상호 유기적으로 작용하여 보다 향상된 기능성이 보장되고, 정장제, 사료첨가제 및 분말 유산균 제품의 제조에 적절히 이용함에 있다.An object of the present invention is to select the lactic acid bacteria that produce the CLA (CLA) by using the lactic acid bacteria in the production of fermented milk, the anti-cancer effect of fermented milk and the anticancer effect of CLA organically interact with each other to ensure improved functionality, Appropriate use in the manufacture of feed additives and powdered lactic acid bacteria products.

이하, 본 발명은 하기의 실시 예에 의해 보다 구체적으로 설명될 것이나, 이러한 실시 예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail by the following examples, but is not limited to these examples.

< 실시예 1 > 씨엘에이(CLA) 생성 유산균의 선발Example 1 Selection of CLA-producing Lactic Acid Bacteria

유산균은 고려대학교 응용동물과학과, 오클라호마 주립 대학 축산학과(미합중국), 코넬대학교 식품공학과(미합중국), 그리고 주식회사 컬쳐시스템(Culture system; 미합중국), 그리고 미국종균협회(ATCC ; American Type Culture Collection)에서 분양받아 사용하였다.Lactobacillus was distributed by Korea University, Department of Applied Animal Science, Oklahoma State University, Livestock (US), Cornell University Food Science (US), Culture System (US), and the American Type Culture Collection (ATCC). Used.

본 실험에 사용한 유산균은 2중량% 트립톤, 효모추출물 0.7중량%, 포도당 2중량%에 증류수로 100이 되도록 보정한 배지에서 혐기적으로 37℃의 항온기에서 배양하였다. 11중량% 탈지분유를 89중량%의 증류수에 용해시켜 제조된 배지에 멸균된 리놀레인산 100 밀리그램 당 리터의 함량으로 첨가한 후 37℃ 항온수조에서 배양하였다.The lactic acid bacteria used in this experiment were incubated anaerobically at 37 ° C. in a medium calibrated to 2% by weight of tryptone, 0.7% by weight of yeast extract, and 2% by weight of glucose to 100 with distilled water. 11 wt% skim milk powder was dissolved in 89 wt% of distilled water, and added to the medium prepared in 100 liters of 100 mg of sterile linoleic acid, followed by culturing in a 37 ° C constant temperature water bath.

상기 배양액을 이소프로파놀과 핵산을 3:2로 혼합된 혼합액에 잘 흔들어서 추출한 다음 원심분리 한 후 상등 액을 취해 2% 황산을 촉매로 이용, 메칠 알코올과 톨루엔 (1:1) 혼합액에서 70℃ 에서 30분간 유도체화를 시킨 후 가스크로마토드래피를 이용하여 분석하여 그 결과를 표 1에 나타내었다.The culture solution was extracted by shaking well with a mixture of isopropanol and nucleic acid in a 3: 2 mixture, followed by centrifugation, taking a supernatant, and using 2% sulfuric acid as a catalyst. 70 ℃ in a mixture of methyl alcohol and toluene (1: 1). After derivatization for 30 minutes at and analyzed using gas chromatographies, the results are shown in Table 1.

유산균의 씨엘에이(CLA) 생성량CLA production amount of lactic acid bacteria 유산균 종류Lactobacillus species 씨엘에이(CLA) 생성량Production of CLA Lactobacillus acidophilusA4 Lactobacillus acidophilus A4 ++++ Lactobacillus acidophilusGP1B Lactobacillus acidophilus GP1B ++++ Lactobacillus acidophilusATCC 43121 Lactobacillus acidophilus ATCC 43121 ++++ Lactobacillus acidophilus30SC Lactobacillus acidophilus 30SC ++++ Lactobacillus acidophilusGP2A Lactobacillus acidophilus GP2A ++++ Lactobacillus acidophilusATCC 4356 Lactobacillus acidophilus ATCC 4356 -- Lactobacillus bulgaricusLactobacillus bulgaricus -- Lactobacillus caseiY2 Lactobacillus casei Y2 ++++ Lactobacillus caseiCU24 Lactobacillus casei CU24 ++++ Lactobacillus caseiY18 Lactobacillus casei Y18 ++++ Lactobacillus helveticusATCC 15009 Lactobacillus helveticus ATCC 15009 __ Bifidobacterium longumATCC 15707 Bifidobacterium longum ATCC 15707 ++++++ Bifidobacterium longumCS1 Bifidobacterium longum CS1 ++++++ Bifidobacterium adolescentisATCC 15073 Bifidobacterium adolescentis ATCC 15073 ++ Bifidobacterium breveATCC 15700 Bifidobacterium breve ATCC 15700 ++++ Bifidobacterium infantisATCC 15697 Bifidobacterium infantis ATCC 15697 ++++

- : 생산하지 않음-: Do not produce

+ : 지질 그램당 3밀리그램 이하 생산+: Less than 3 milligrams per gram of lipid

++ : 지질 그램당 3밀리그램 이상, 5밀리그램 이하 생산++: Produces more than 3 and less than 5 milligrams per gram of lipid

+++ : 지질 그램당 5밀리그램 이상 생산+++: Produce more than 5 milligrams per gram of lipid

상기 표 1에서 보여주는 바와 같이, 씨엘에이(CLA) 생산능에 있어 비피도박테리아 롱검이 다른 종류의 유산균보다 우수하게 나타났으며, 락토바실러스 카제이균과 락토바실러스 애시도 필러스 균도 씨엘에이(CLA)를 다소 생산하는 것으로 나타났다.As shown in Table 1, Bifidobacteria long gum was superior to other types of lactic acid bacteria in the production capacity of CLA, and Lactobacillus casei and Lactobacillus ashdophyllus bacteria were also CLA (CLA). It appeared to produce somewhat.

< 실시예 2 > 씨엘에이(CLA) 함유 발효유의 제조무지 유고형분을 조절한 원유(실험예 1 ; 원유 96중량% + 탈지분유 3중량% + 해바라기씨 기름 1중량%, 실험예 2 ; 정제수 95중량% + 탈지분유 4중량% + 해바라기씨 기름 1중량%, 실험예 3 ; 원유 96중량% + 탈지분유 3중량% + 해바라기씨 기름 1중량%)를 혼합하고, 균질화한 다음, 선발된 유산균을 스타아터로 만들어 첨가한 후 30~45℃의 온도에서 배양하여 배양액을 제조하였다.<Example 2> Crude oil (CLA) -containing fermented milk Crude milk (Experimental Example 1; crude oil 96% by weight + skim milk powder 3% by weight + sunflower seed oil 1% by weight, Experimental Example 2; purified water 95 Wt% + skimmed milk powder 4% + sunflower seed oil 1% by weight, Experimental Example 3: crude oil 96% by weight + skimmed milk powder 3% by weight + sunflower seed oil 1% by weight), homogenized, and then selected lactic acid bacteria After the addition to make a star theater, the culture solution was prepared by incubating at a temperature of 30 ~ 45 ℃.

이렇게 제조된 배양액에 기호성을 증진시키기 위하여 각각 고과당 6중량%, 과즙 10중량% 및 상기 실험예들의 배양액 84중량%를 혼합하여 표 3에서와 같이, 관능특성을 포함한 이화학적 특성을 조사하였다.In order to enhance palatability in the culture solution thus prepared, 6 wt% of high fructose, 10 wt% of fruit juice, and 84 wt% of the culture solution of the above experimental examples were mixed, and the physicochemical properties including the sensory properties were examined as shown in Table 3.

씨엘에이(CLA) 함유 발효유의 이화학적 특성 비교Comparison of Physicochemical Properties of Fermented Milk Containing CLA 페하(pH)PH (pH) 이 취This odor 씨엘에이함량1)(mg/g 지방)CL content 1) (mg / g fat) 기호성2) Palatability 2) 신 맛3) Sour taste 3) 실험예 1Experimental Example 1 4.114.11 없음none 8.468.46 77 66 실험예 2Experimental Example 2 4.184.18 없음none 3.623.62 66 66 실험예 3Experimental Example 3 4.234.23 없음none 7.647.64 44 55 비교예 14) Comparative Example 1 4) 4.144.14 없음none 2.112.11 77 66 비교예 25) Comparative Example 2 5) 4.294.29 없음none 0.650.65 55 44

1)씨엘에이 함량은 지질 그램당 밀리그램을 의미함 1) CC content means milligrams per gram of lipid

2)기호성 : 9 (아주 좋다) ∼ 1 (아주 싫다) 2) Palatability: 9 (very good) to 1 (very much)

3)신 맛 : 9 (아주 강하다) ∼ 1 (아주 약하다) 3) Sour taste: 9 (very strong) to 1 (very weak)

4)비교예 1 : 시판 농후 발효유 (무지유고형분 8중량% 이상의 원유) 4) Comparative Example 1: Commercially enriched fermented milk (crude oil solid content of 8% by weight or more)

5)비교예 2 : 시판 액상 발효유 (무지유고형분 8중량% 이하의 원유) 5) Comparative Example 2: Commercial liquid fermented milk (crude oil of 8% by weight or less solid oil)

상기 표 3에서 보여주는 바와 같이, 본 발명의 씨엘에이를 함유 발효유는 무지유 고형분 8% 인 경우 기존의 농후 발효유 보다 씨엘에이를 3배이상 함유하는 것으로 확인되었으며, 무지유 고형분이 4%인 경우에는 기존의 액상발효유 보다 약 6배 이상 함유하였다. 또한 pH나 기호성에서 기존 제품과 별 차이가 없이 우수하게 나타났다.As shown in Table 3, the fermented milk containing the CL of the present invention was confirmed to contain more than three times the SL of the conventional rich fermented milk when the non-fat solid content of 8%, the non-fat solid content of 4% It contained about 6 times more than conventional liquid fermented milk. In addition, pH or palatability was excellent without any difference from existing products.

< 실시예 3 > 동물실험을 통한 항암효과 비교Example 3 Comparison of Anticancer Effects through Animal Experiments

6주령 무균 자성 마우스를 중국 암연구소에서 구입하여 케이지당 5마리씩으로 하여 예비 사육한 다음 사용하였는데, 이때 사육실은 각각 12시간씩 점등을 조절하였으며 물과 조제사료는 자유섭취 하도록 하였다.Six-week-old sterile magnetic mice were purchased from the Chinese Cancer Research Institute, and were used after preliminary breeding with 5 birds per cage. At this time, the breeding room was controlled for 12 hours each, and the water and the feed were freely ingested.

원유 중의 무지 유고형분을 8중량%로 조정한 원유 99중량%에 해바라기씨 기름 1중량%를 첨가하여 균질화 한 다음 씨엘에이(CLA)를 생산하는 유산균의 하나인 비피도박테리움 롱검을 배양시킨 배양액 또는 배양 후 균체를 건조시킨 분말을 접종하여 30-45℃ 온도로 배양시킨 다음 pH가 4.7∼4.2가 되면 배양을 종료하여 발효유를 제조하였으며 제조된 발효유를 이용하여 동물실험에 사용하였다. 발암물질인 벤조피렌(Benzopyrene)을 이용하여 전위(前胃)암을 유발시킨 후 각각의 제조된 요구르트를 물로 2배 희석하여 4주 동안 자유로이 섭취하도록 하였고, 대조군 1은 물과 조제 사료만 섭취하도록 하였고, 대조군 2는 일반 발효유를, 대조구 3은 해바라기씨 오일을 동일한 방법으로 섭취하도록 하였다.A culture medium in which Bifidobacterium longgum, one of lactic acid bacteria producing CLA, was homogenized by adding 1% by weight of sunflower seed oil to 99% by weight of crude oil adjusted to 8% by weight of solid milk solids in crude oil. Alternatively, after incubation, the cells were inoculated with the dried powder and incubated at a temperature of 30-45 ° C., and when the pH reached 4.7˜4.2, the culture was terminated to prepare fermented milk, which was used in animal experiments using the prepared fermented milk. After inducing potential cancer by using benzopyrene, a carcinogen, each prepared yogurt was diluted twice with water for free intake for 4 weeks. , Control 2 was to consume normal fermented milk, control 3 was to consume sunflower seed oil in the same way.

표 4에서 제시된 바와 같이 발암율을 비교하여 보면, 씨엘에이 함유 발효유군은 53.3%로 대조군들에 비해서 매우 낮은 것으로 나타나 본 씨엘에이 함유 발효유의 투여는 전위암 생성을 효과적으로 억제시킴을 알 수 있었다.As shown in Table 4, when comparing the carcinogenicity rate, the fermented milk group containing the CLA was 53.3%, which is very low compared to the control group, and the administration of the CLA-containing fermented milk effectively inhibited the generation of dislocation cancer.

씨엘에이(CLA) 함유 발효유의 항암효과 비교Comparison of Anticancer Effects of Fermented Milk Containing CLA 실험군Experimental group 실험에 사용된동물 수Number of animals used in the experiment 암이 유발된동물 수Cancer-causing animals 발암율(%)Carcinogenicity rate (%) 대조군 1(물)Control group 1 (water) 1515 1515 100.0100.0 대조군 2(일반 발효유)Control Group 2 (General Fermented Milk) 1515 1313 86.786.7 대조군 3(해바라기씨 기름)Control Group 3 (Sunflower Seed Oil) 1515 1414 93.393.3 씨엘에이(CLA) 함유 발효유Fermented milk containing CLA 1515 88 53.3*53.3 *

* 유의적 차이가 인정되었음 (P<0.01)* Significant difference was recognized (P <0.01)

이상에서 상세히 살펴본 바와 같이, 본 발명은 높은 항동맥 경화와 항암효과를 지닌 것으로 밝혀진 씨엘에이(CLA)를 생성하는 유산균을 선발하여 그 유산균을 발효유 제조에 이용함으로서, 발효유의 정장효과와 CLA의 항암효과가 상호 유기적으로 작용하여 보다 향상된 기능성이 보장되어 인체 건강에 유용하게 활용될 수 있는 효과와 정장제, 사료첨가제 및 분말 유산균 제품의 제조에 적절히 이용할 수 있음으로서 산업발전에 유용한 효과가 있다.As described in detail above, the present invention is to select the lactic acid bacteria that produce CLA (CLA) that has been found to have a high anti-arteriosclerosis and anti-cancer effect and by using the lactic acid bacteria in fermented milk production, the formal effect of fermented milk and anti-cancer of CLA The effects are mutually organic to ensure improved functionality, and can be effectively used for human health, and can be suitably used for the preparation of suits, feed additives, and powdered lactic acid bacteria products, which are useful for industrial development.

Claims (5)

(정정)비피도박테리움 롱검 ATCC 15707를 이용하여 발효유 내의 유효성분으로 씨엘에이(CLA, Conjugated linoleic acid)를 0.2∼2중량%를함유하는 것을 특징으로 하는 CLA를 함유하는발효유 조성물.(Correction) A fermented milk composition containing CLA, comprising 0.2 to 2% by weight of CLA (conjugated linoleic acid) as an active ingredient in fermented milk using Bifidobacterium long gum ATCC 15707 . (정정) 제1항에 있어서,(Correction) The method according to claim 1, 상기 씨엘에이(CLA)를 생산하는 기질이나 효과 강화를 목적으로 해바라기씨 기름을0.5~2중량%로 첨가하여 비피도박테리움 롱검 ATCC 15707을 스타아터로 사용하는 것을특징으로 하는 CLA를 함유하는 발효유 조성물.Fermented milk containing CLA, characterized in that Bifidobacterium long gum ATCC 15707 is used as a starter by adding 0.5 to 2% by weight of sunflower seed oil for the purpose of enhancing the substrate or effect of producing CLA. Composition. (삭제)(delete) (삭제)(delete) (삭제)(delete)
KR10-2000-0014858A 2000-03-23 2000-03-23 Development of fermented dairy products containing CLA KR100371549B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2000-0014858A KR100371549B1 (en) 2000-03-23 2000-03-23 Development of fermented dairy products containing CLA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2000-0014858A KR100371549B1 (en) 2000-03-23 2000-03-23 Development of fermented dairy products containing CLA

Publications (2)

Publication Number Publication Date
KR20010089858A KR20010089858A (en) 2001-10-12
KR100371549B1 true KR100371549B1 (en) 2003-02-06

Family

ID=19657948

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-0014858A KR100371549B1 (en) 2000-03-23 2000-03-23 Development of fermented dairy products containing CLA

Country Status (1)

Country Link
KR (1) KR100371549B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634502A1 (en) * 2004-09-10 2006-03-15 Cognis IP Management GmbH Emulsions containing unsaturated fatty acids and esters thereof
KR100953915B1 (en) 2007-12-20 2010-04-22 고려대학교 산학협력단 A method for preparing a cheese having rich conjugated linoleic acid by controlling lactating time, feeding regimen and ripening

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2481894C (en) * 2002-04-12 2010-06-01 Kabushiki Kaisha Yakult Honsha Process for producing conjugated fatty acid and food/drink produced by the process
KR100515850B1 (en) * 2003-06-28 2005-09-21 윤칠석 A Bifidobacterium breve LMC520 strain containing a plasmid pBC520, a method for preparation of conjugated fatty acids and fermented milks containing such fatty acids using the same strain, and use of a plasmid pBC520
CN101686696A (en) * 2007-04-24 2010-03-31 脂质营养品有限公司 Low sugar yoghurt
KR101401530B1 (en) * 2012-07-06 2014-06-11 (주)케비젠 Bifidobacterium longum strain producing conjugated linoleic acid and uses thereof
KR101726416B1 (en) * 2015-10-08 2017-04-14 재단법인 임실치즈앤식품연구소 Fermented milk including Conjugated linoleic acid having Anti-diabetic effect and the manufacturing method thereof
CN114958662B (en) * 2022-05-13 2023-10-03 江南大学 Bifidobacterium longum subspecies capable of relieving constipation and up-regulating IL-10 to relieve inflammation and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856149A (en) * 1995-06-01 1999-01-05 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856149A (en) * 1995-06-01 1999-01-05 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634502A1 (en) * 2004-09-10 2006-03-15 Cognis IP Management GmbH Emulsions containing unsaturated fatty acids and esters thereof
KR100953915B1 (en) 2007-12-20 2010-04-22 고려대학교 산학협력단 A method for preparing a cheese having rich conjugated linoleic acid by controlling lactating time, feeding regimen and ripening

Also Published As

Publication number Publication date
KR20010089858A (en) 2001-10-12

Similar Documents

Publication Publication Date Title
US5516684A (en) Biologically pure culture of Lactobacillus acidophilus FERM-P-14204 or FERM-P-14205
MXPA01012460A (en) A bacterial strain, processed plant extracts and probiotic compositions for human and veterinary use.
JP5247012B2 (en) Fatty liver suppressant
US11484583B2 (en) Intestinal bacteria Butyribacter intestini and application thereof
KR20110081202A (en) Lactic acid bacterium having high oxalic acid decomposition ability
AU2011300738B2 (en) Lactococcus lactis strain with high vitamin K2 production
US8673616B2 (en) Lactococcus lactis strain with high vitamin K2 production
ABD EL‐SALAM et al. Screening of some potentially probiotic lactic acid bacteria for their ability to synthesis conjugated linoleic acid
KR100371549B1 (en) Development of fermented dairy products containing CLA
JPWO2018003900A1 (en) Composition for use in improving nutritional status
JP5847587B2 (en) Propionic acid bacterium-containing composition and method of using the same
JP6762855B2 (en) Muscle breakdown inhibitor
WO2015182155A1 (en) Novel lactic acid bacterium and composition including said lactic acid bacterium
US10307445B2 (en) Bacterial strains having an outstanding ability to produce menaquinone
CN110982731A (en) Space-induced lactobacillus plantarum ST20-71 with probiotic characteristics and application thereof
EP0587657A1 (en) Food additive for human and animal foodstuffs and foodstuffs containing same
EP3479836A1 (en) Cartilage regeneration facilitating composition
EP2746398A1 (en) Process for producing conjugated linolenic acid from linolenic acid employing Bifidobacterium breve, Bifidobacterium bifidum, or Lactobacillus oris strains.
KR100417390B1 (en) Novel Microorganism of Bifidobacterium breve LMC7 Bifidus strain, Method for Production of Conjugated Fatty Acid and Fermented Milk using Said Microorganism
TW202242090A (en) Lactic acid bacteria composition for reducing fat and promoting exercise performance and use therefor
KR0157757B1 (en) Separation method for bifidobacterium which has acid tolerance

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080124

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee